...Catalina Hartmann Skovsgård; Trine Bay Laurberg; Anders Dige; Lars Iversen; Kasper Fjellhaugen Hjuler Background: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that occurs in a large proportion of patients with psoriasis causing pain and impaired quality of life. Early recognition...

..., physician-given diagnosis of moderate to severe psoriasis (body surface area [BSA] >5% to <10%, affecting sensitive and/or prominent body parts or BSA ≥10%) at its worst, with/without psoriatic arthritis (PsA). Patients were recruited through online panels by the Institut de Publique Sondage d’Opinion...

...Juliëtte N. Pouw; Marleen E. Jacobs; Deepak M.W. Balak; Jacob M. van Laar; Paco M.J. Welsing; Emmerik F.A. Leijten Background: Early identification of patients at risk of psoriatic arthritis (PsA) is essential to facilitate early diagnosis and improve clinical outcomes. Severe cutaneous psoriasis...

...Augusta Ortolan; Mariagrazia Lorenzin; Giovanni Leo; Francesca Pampaloni; Francesco Messina; Andrea Doria; Stefano Piaserico; Roberta Ramonda Background: Secukinumab effectiveness has been demonstrated in both psoriasis (PsO) and psoriatic arthritis (PsA). However, it is unknown whether patients...

...Georgios Kokolakis; Kasper Vadstrup; Jes B. Hansen; Jose Manuel Carrascosa Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that significantly impairs physical function and quality of life (QoL). Prompt therapeutic intervention is crucial...

..., insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23–24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis...

... and depression in psoriatic arthritis (PsA) patients. Methods: A total of 70 PsA patients were enrolled. Demographic and clinical characteristics were collected after enrollment. HADS-A and SAS were used to evaluate the anxiety of PsA patients, while HADS-D and SDS were used to evaluate the depression of PsA...

...: Psoriatic arthritis (PsA) is preceded by psoriasis in approximately 80% of cases. Dermatologists are pivotal for early detection. It is important to have simple tools that allow the detection of PsA in patients with skin psoriasis. The aim of our study was to evaluate the performance of an adapted version...

... and regulation of autoimmune and inflammatory diseases. In this study, we aimed to explore the impact of these new ILs in psoriasis (Ps) and psoriatic arthritis (PsA). Methods: Forty PsA patients, 20 Ps patients, and 20 healthy controls (HCs) were recruited. Blood samples were obtained for detecting the levels...

...Peter Härle; Katrin Letschert; Bianca Wittig; Ulrich Mrowietz Early detection of psoriatic arthritis (PsA) remains a challenge in clinical practice. Tools such as the German Psoriasis Arthritis Diagnostic (GEPARD) questionnaire have been developed for this purpose. The aim of this study...

...Diamant Thaçi; Frank Behrens; Gerd Greger; Harald Burkhardt; Holger Gnann; Rudolf Schopf; Bianca Maria Wittig Background: The association between skin and joint manifestations in patients with psoriatic arthritis (PsA) requires further characterization. Objective: We evaluated the association...

...Wolf-Henning Boehncke; Mark David Anliker; Curdin Conrad; Jean Dudler; Fritz Hasler; Paul Hasler; Peter Häusermann; Diego Kyburz; Emmanuel Laffitte; Beat A. Michel; Burkhard Möller; Alexander A. Navarini; Peter M. Villiger; Nikhil Yawalkar; Cem Gabay Background: Psoriatic arthritis (PsA...

... of their clinical, inflammatory, and quality of life indexes. Conclusion: Data suggest that GLB can be successful and safe in patients affected by PsA with skin involvement previously treated with other anti-TNF-α agents. 20 02 2013 1 07 2013 19 11 2013 Golimumab Psoriatic arthritis...

... of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. Methods: Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin...

...Dennis G. McGonagle; Philip Helliwell; Douglas Veale Enthesitis is increasingly recognized as an important component in psoriatic arthritis (PsA). Improved imaging techniques have expanded our understanding of the role of enthesitis in PsA and provided methods for earlier detection and assessment...

... assessment. Results: Over 86% of psoriatic arthritis (PsA) patients reported presenting with psoriasis prior to PsA; the diagnosis of psoriasis preceded that of PsA by a mean period of 14.6 years. Compared to those with mild psoriasis, patients with moderate-to-severe psoriasis had significantly increased...

... developed incapacitating palmoplantar pustulosis and psoriasis vulgaris flare with severe scalp and nail involvement after 5 months of treatment with adalimumab for psoriatic arthritis. Several treatments, including topical corticosteroids, photochemotherapy, ciclosporin, acitretin and etanercept 50 mg...

... the higher prevalence of nail involvement in psoriatic arthritis (PsA). The purpose of this study was to determine whether such anatomical factors might also be associated with different patterns of nail involvement in skin psoriasis and PsA. Methods: A total of 173 patients were recruited: 121 PsA cases...

...Paolo Gisondi; Ilaria Tinazzi; Micol Del Giglio; Giampiero Girolomoni Psoriasis is a complex disease involving the skin, nails and musculoskeletal structures. Psoriatic arthritis (PsA) affects peripheral joints, entheses, the synovial sheaths of tendons and the axial skeleton. PsA is now recognised...

...Philip J. Mease; James Signorovitch; Andrew P. Yu; Eric Q. Wu; Shiraz R. Gupta; Yanjun Bao; Parvez M. Mulani Background: Psoriatic arthritis often affects patients with psoriasis. Objective: To examine the effect of adalimumab on psoriatic arthritis in patients with moderate to severe psoriasis...